IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1001-1025 out of 1422.

<< < 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 > >>

Public Release: 25-Mar-2016
Kidney International
Study shows that Wnt secretion preventing drugs may reduce renal fibrosis
Renal fibrosis or the scarring of kidneys, following an injury, reduces their function and can cause kidney disease to progressively worsen. In a recent study, published in Kidney International, researchers from Duke-NUS Medical School (Duke-NUS) in Singapore and Duke University have shown that drugs that target Wnt secretion by inhibiting Porcupine, a protein usually targeted for cancer treatment, may reduce renal fibrosis and protect the kidneys.
Duke/Duke-NUS Research Collaboration Pilot Project Award

Contact: Dharshini Subbiah
dharshini.subbiah@duke-nus.edu.sg
659-616-7532
Duke-NUS Medical School

Public Release: 24-Mar-2016
American College of Cardiology 2016 Scientific Session
JACC: Cardiovascular Imaging
Mammograms: Another way to screen for heart disease?
Routine mammography -- widely recommended for breast cancer screening -- may also be a useful tool to identify women at risk for heart disease, potentially allowing for earlier intervention, according to a study scheduled for presentation at the American College of Cardiology's 65th Annual Scientific Session.

Contact: Nicole Napoli
nnapoli@acc.org
202-375-6523
American College of Cardiology

Public Release: 24-Mar-2016
Science
Cancer cells show resilient nuclear rupture repair, but expose weakness in doing so
A new study led by Cornell University engineers finds that cancer cells have a resilient ability to repair themselves, but the nuclear deformation and rupture can compromise the genomic integrity of the cancer cells, which could drive further cancer progression.

Contact: Daryl Lovell
dal296@cornell.edu
607-592-3925
Cornell University

Public Release: 24-Mar-2016
JAMA Oncology
Economic analysis of PSA screening, selective treatment strategies
Can prostate-specific antigen (PSA) screening for prostate cancer be cost-effective? A study, commentary and author interview published online by JAMA Oncology examines that question.

Contact: Kristin Woodward
kwoodwar@fredhutch.org
206-667-5095
The JAMA Network Journals

Public Release: 24-Mar-2016
Journal of Palliative Medicine
Potential for misuse & diversion of opioids to addicts should not overshadow their therapeutic value
Opioids are very effective for treating some types of pain, such as cancer pain and postoperative pain, but not for other kinds of pain like chronic low back pain. An increase in the number of opioid-related deaths among addicts has led to the current movement to restrict opioid prescribing by state and federal authorities. While a laudable goal, these restrictions threaten to block their use for safe and effective pain relief when medically indicated.

Contact: Kathryn Ryan
kryan@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News

Public Release: 24-Mar-2016
Nano Letters
Microneedle patch delivers localized cancer immunotherapy to melanoma
Biomedical engineering researchers have developed a technique that uses a patch embedded with microneedles to deliver cancer immunotherapy treatment directly to the site of melanoma skin cancer. In animal studies, the technique more effectively targeted melanoma than other immunotherapy treatments.
National Institutes of Health

Contact: Matt Shipman
matt_shipman@ncsu.edu
919-515-6386
North Carolina State University

Public Release: 24-Mar-2016
ATS supports Osha's more protective crystalline silica exposure standard
While it took nearly three years of waiting, the American Thoracic Society is pleased that OSHA has issued its final rule establishing a more protective standard for occupational silica. The new more protective standard will greatly reduce exposure to this known and potentially deadly occupational hazard.

Contact: Dacia Morris
dmorris@thoracic.org
212-315-8620
American Thoracic Society

Public Release: 23-Mar-2016
Nature Communications
Decreased blood vessel leakage can improve cancer therapy and reduce tumor spread
Cancer therapy is often hampered by the accumulation of fluids in and around the tumor, which is caused by leakage from the blood vessels in the tumor. Researchers at Uppsala University now show how leakage from blood vessels is regulated. They have identified a novel mechanism whereby leakage can be suppressed to improve the result of chemotherapy and reduce the spread of tumors in mice. The results have been published in the scientific journal Nature Communications.

Contact: Lena Claesson-Welsh
lena.welsh@igp.uu.se
46-701-679-260
Uppsala University

Public Release: 23-Mar-2016
New England Journal of Medicine
New imaging scans track down persistent cancer cells
Head and neck cancer patients may no longer have to undergo invasive post-treatment surgery to remove remaining cancer cells, as research shows that innovative scanning-led surveillance can help identify the need for, and guidance of, neck dissection.

Contact: Luke Harrison
l.harrison.1@bham.ac.uk
University of Birmingham

Public Release: 23-Mar-2016
PLOS ONE
New proteins discovered that link obesity-driven diabetes to cancer
For the first time, researchers have determined how bromodomain (BRD) proteins work in type 2 diabetes, which may lead to a better understanding of the link between adult-onset diabetes and certain cancers.
NIH/National Cancer Institute

Contact: Gina DiGravio
ginad@bu.edu
617-638-8480
Boston University Medical Center

Public Release: 23-Mar-2016
Nature
VIB, KU Leuven and UGent achieve breakthrough in diagnosis of melanoma skin cancer
In collaboration with researchers from UGent, VIB scientists from KU Leuven have revealed a remarkable link between malignant melanoma and a non-coding RNA gene called SAMMSON. The SAMMSON gene is expressed in human malignant melanoma and, strikingly, the growth of aggressive skin cancer is highly dependent on this gene. The conclusions could pave the way for improved diagnostic tools and skin cancer treatment.

Contact: Sooike Stoops
sooike.stoops@vib.be
32-924-46611
VIB (the Flanders Institute for Biotechnology)

Public Release: 23-Mar-2016
Scientific Reports
Brad Pitt's and fruit flies' cowlicks controlled by cancer protein
What does Brad Pitt have in common with a fruit fly? His Hollywood hairstyles cover a prominent cowlick -- the swirl of hair that that is caused by a patterning mechanism also active in our two-winged friends -- that similarly feature 'polarized' hair patterns.
National Institutes of Health

Contact: Layne Cameron
layne.cameron@cabs.msu.edu
517-353-8819
Michigan State University

Public Release: 23-Mar-2016
Journal of Magnetic Resonance Imaging
NIST develops first widely useful measurement standard for breast cancer MRI
Researchers at the National Institute of Standards and Technology (NIST) have developed the first widely useful standard for magnetic resonance imaging (MRI) of the breast, a method used to identify and monitor breast cancer.

Contact: Laura Ost
laura.ost@nist.gov
National Institute of Standards and Technology (NIST)

Public Release: 23-Mar-2016
Biotechnology and Bioengineering
Model of tumor spreading may help doctors pinpoint best treatment
Researchers at the Wake Forest Institute for Regenerative Medicine have invented a metastasis-on-a-chip system that is believed to be one of the first laboratory models of cancer spreading from one 3-D tissue to another. They hope it can one day be used to evaluate potential treatments for individual patients and to learn if and where a patient's tumor is likely to spread.
Golfers Against Cancer, Comprehensive Cancer Center at Wake Forest Baptist, Wake Forest Institute for Regenerative Medicine Promoting Discoveries Award

Contact: Karen Richardson
krchrdsn@wakehealth.edu
336-716-4453
Wake Forest Baptist Medical Center

Public Release: 23-Mar-2016
Journal of Community Psychology
Chronic diseases may negatively affect the mental health of poor and middle-income adults
In a study of more than 8,000 adults, those with a chronic health condition such as diabetes or asthma were more likely to report psychological distress and functional impairment if they were residents of poor or middle-income households.

Contact: Dawn Peters
sciencenewsroom@wiley.com
781-388-8408
Wiley

Public Release: 22-Mar-2016
JAMA
Drug combination reduces polyps for patients with high risk for colorectal cancer
In a study appearing in the March 22/29 issue of JAMA, Deborah W. Neklason, Ph.D., N. Jewel Samadder, M.D., M.S., of the Huntsman Cancer Institute, University of Utah, Salt Lake City, and colleagues randomly assigned 92 patients with familial adenomatous polyposis to the drugs sulindac twice daily and erlotinib daily (n = 46) or placebo (n = 46) for 6 months.

Contact: Linda Aagard
Linda.Aagard@hci.utah.edu
801-587-7639
The JAMA Network Journals

Public Release: 22-Mar-2016
CA: A Cancer Journal for Clinicians
New guideline addresses long-term needs of head and neck cancer survivors
A new American Cancer Society guideline provides clinicians with recommendations on key areas of clinical follow-up care for survivors of head and neck cancer.
Centers for Disease Control and Prevention

Contact: David Sampson
david.sampson@cancer.org
American Cancer Society

Public Release: 22-Mar-2016
JAMA
New treatment reduces precancerous polyps in hereditary cancer patients
Inheriting a mutation in the APC gene leads to a nearly 100 percent lifetime risk of colorectal cancer. A new study published in the Journal of the American Medical Association, has identified the first prevention treatment for these patients, a two-drug combination that significantly reduces the number and size of precancerous polyps in the small intestine.
NIH/National Cancer institute, Huntsman Cancer Institute, Huntsman Cancer Foundation, American College of Gastroenterology, National Institutes of Health

Contact: Linda Aagard
linda.aagard@hci.utah.edu
801-587-7639
University of Utah Health Sciences

Public Release: 22-Mar-2016
Journal of Biological Chemistry
Lymphoma overrides a key protein's quadruple locks
Protein chemists at Johns Hopkins report they are closer to explaining why certain blood cancers are able to crack a molecular security system and run rampant.
NIH/National Cancer Institute, Johns Hopkins University Institute for Cell Engineering, Leukemia and Lymphoma Society

Contact: Catherine Gara
ckolf@jhmi.edu
443-287-2251
Johns Hopkins Medicine

Public Release: 22-Mar-2016
Journal of Internal Medicine
Why do sunbathers live longer than those who avoid the sun?
New research looks into the paradox that women who sunbathe are likely to live longer than those who avoid the sun, even though sunbathers are at an increased risk of developing skin cancer.

Contact: Dawn Peters
sciencenewsroom@wiley.com
781-388-8408
Wiley

Public Release: 22-Mar-2016
Journal of Hepatology
More cost-effective cure for hepatitis C may be close
The cost of treating hepatitis C virus could be cut up to 50 percent if mathematical models are used to predict when patients can safely stop taking direct-acting antiviral medication, according to a new study by researchers at Loyola University Health System and Loyola University Chicago.

Contact: Stasia Thompson
thompson539@att.net
708-543-7377
Loyola University Health System

Public Release: 22-Mar-2016
Mount Sinai first hospital to treat liver cancer with radiopaque bead
The M1 LUMI™ Bead provides visible confirmation during embolization treatment for liver cancer.

Contact: Lucia Lee
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine

Public Release: 22-Mar-2016
Journal of Drug Targeting
Scientists distinguish molecules most capable of fighting prostate cancer
Scientists from MIPT (Moscow Institute of Physics and Technology), MSU (Moscow State University), and National University of Science and Technology 'MISIS' provided an overview of the most promising compounds which can be used as medications for prostate cancer. The article was published in the Journal of Drug Targeting.

Contact: Valerii Roizen
press@mipt.ru
7-929-992-2721
Moscow Institute of Physics and Technology

Public Release: 22-Mar-2016
Cancer Research
Many targeted cancer therapies suppress T cell immune responses
New research from The Wistar Institute demonstrated that dozens of these targeted therapies suppressed the activity of T cells that could actually help fight tumors. While studying the FDA-approved targeted therapy trametinib, the researchers also found that pairing it with a signaling protein 'superagonist' stimulated T cell activity while preserving the cancer-blocking effects of the cancer treatment.
National Institutes of Health, Jayne Koskinas Ted Giovanis Foundation Breast Cancer Research Consortium, Ovarian Cancer Research Fund

Contact: Ben Leach
bleach@wistar.org
215-495-6800
The Wistar Institute

Public Release: 21-Mar-2016
Lancet Oncology
High-risk lung cancer patients may not need annual screenings
Most high-risk lung cancer patients might not need annual low-dose computed tomography (LDCT) screenings if they are cleared of disease in their initial test, according to a study led by a Duke Cancer Institute researcher.

Contact: Sarah Avery
sarah.avery@duke.edu
919-660-1306
Duke University Medical Center

Showing releases 1001-1025 out of 1422.

<< < 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 > >>

  Search News Releases

     

 

EurekAlert!